Alzinova Competitors
| ALZ Stock | SEK 0.73 -0.02 -2.67% |
Alzinova vs Pila Pharma Correlation Overview
Poor diversification
ALZ currently posts a 0.68 correlation with PILA, indicating a Poor diversification relationship for the active sample. This matters because lower overlap can improve diversification, while higher overlap leaves more of the same risk inside the portfolio.
Moving together with Alzinova Stock
Moving against Alzinova Stock
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Alzinova's price to converge to an average value over time is called mean reversion.
Alzinova Competition Correlation Matrix
Correlation analysis between Alzinova AB and its competitors helps investors understand whether diversification is real or only superficial inside the same peer group. This matrix is most informative when investors want to know whether adding another peer would improve diversification, increase crowding, or leave total risk largely unchanged.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Alzinova Stock performing well and Alzinova Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Alzinova's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| XBRANE | 3.66 | -0.42 | 0.00 | -0.35 | 0.00 | 7.26 | 30.97 | |||
| BRAIN | 2.97 | 0.17 | 0.04 | 0.72 | 3.64 | 6.67 | 18.95 | |||
| ANNX | 4.22 | -0.58 | 0.00 | 2.51 | 0.00 | 9.04 | 44.62 | |||
| CMOTEC-B | 4.40 | -0.06 | 0.00 | -0.15 | 0.00 | 10.86 | 25.29 | |||
| NICA | 3.55 | -1.06 | 0.00 | 2.39 | 0.00 | 7.89 | 36.31 | |||
| ISOFOL | 2.65 | -0.02 | 0.00 | -0.07 | 0.00 | 2.99 | 50.92 | |||
| KLAR | 5.14 | 1.01 | 0.18 | 0.60 | 4.93 | 13.79 | 34.96 | |||
| LIPUM | 0.79 | -0.12 | 0.00 | -0.25 | 0.00 | 1.75 | 5.07 | |||
| PILA | 4.40 | -0.66 | 0.00 | -1.36 | 0.00 | 9.86 | 51.16 |
Alzinova Competitive Analysis
Within its peer group that includes Xbrane Biopharma, BrainCool, and Annexin Pharmaceuticals, Alzinova stands out in several ways. The company commands a 139.0 M market valuation. Profitability is a concern, with a -67.75% net margin and -10.74% return on equity signaling pressure on earnings. On pure scale, Xbrane Biopharma is the bigger entity with market caps of 2.74 B versus 139.0 M. Market capitalization diverges sharply here: 139.0 M versus 106,733, giving Alzinova a clear size advantage. Alzinova converts shareholder equity more efficiently at -10.74% versus Annexin Pharmaceuticals at -105.95%.| Better Than Average | Worse Than Peers | View Performance Chart |
Peer Performance Charts
How to Analyze Alzinova Against Peers
Alzinova's peer analysis compares Alzinova with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Alzinova trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Alzinova leads or lags and what catalysts could close or widen the gap.